# CytomX Therapeutics (CTMX) — Earnings

CTMX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ctmx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.09 |
| EPS estimate | −$0.08 |
| EPS surprise | −16.73% |
| Revenue surprise | −88.55% |
| Revenue | $1.4M |
| Revenue estimate | $12.4M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1501989/000119312526337950/ctmx-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/a2cfcd79-942a-4b00-a58c-bda7ba56041c.html) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.08 | −$0.09 | -16.73% | $12.4M | $1.4M |
| Q1 2026 | May 7, 2026 | −$0.12 | −$0.10 | 17.42% | $4.7M | $10.3M |
| Q4 2025 | Mar 16, 2026 | −$0.09 | −$0.17 | -85.42% | $7.3M | $661,000.00 |
| Q3 2025 | Nov 6, 2025 | −$0.05 | −$0.09 | -82.56% | $11.4M | $6.0M |
| Q2 2025 | Aug 7, 2025 | −$0.06 | $0.00 | 100.00% | $18.8M | $18.7M |
| Q1 2025 | May 12, 2025 | $0.12 | $0.27 | 116.35% | $35.5M | $50.9M |
| Q4 2024 | Mar 6, 2025 | −$0.20 | $0.22 | 212.65% | $13.0M | $38.1M |
| Q3 2024 | Nov 7, 2024 | −$0.17 | $0.07 | 140.63% | $17.1M | $33.4M |
| Q2 2024 | Aug 8, 2024 | −$0.10 | −$0.08 | 19.84% | $20.0M | $25.1M |
| Q1 2024 | May 8, 2024 | −$0.10 | $0.17 | 266.50% | $19.4M | $41.5M |
| Q4 2023 | Mar 11, 2024 | −$0.05 | $0.02 | 141.41% | $19.6M | $26.6M |
| Q3 2023 | Nov 7, 2023 | −$0.19 | $0.04 | 121.21% | $13.3M | $26.4M |
| Q2 2023 | Aug 8, 2023 | −$0.19 | −$0.02 | 89.42% | $13.7M | $24.7M |
| Q1 2023 | May 9, 2023 | −$0.11 | −$0.05 | 54.87% | $19.9M | $23.5M |
| Q4 2022 | Mar 27, 2023 | −$0.24 | −$0.42 | -78.27% | $18.1M | $947,000.00 |
| Q3 2022 | Nov 8, 2022 | −$0.30 | −$0.35 | -14.83% | $18.2M | $16.9M |
| Q2 2022 | Aug 4, 2022 | −$0.37 | −$0.37 | 0.86% | $18.1M | $18.2M |
| Q1 2022 | May 5, 2022 | −$0.36 | −$0.37 | -3.41% | $21.2M | $17.1M |
| Q4 2021 | Mar 1, 2022 | −$0.35 | −$0.39 | -12.62% | $19.6M | $19.7M |
| Q3 2021 | Nov 4, 2021 | −$0.31 | −$0.35 | -11.89% | $18.4M | $17.6M |

## Frequently Asked Questions

### When did CytomX Therapeutics (CTMX) last report earnings?

CytomX Therapeutics last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did CTMX beat earnings estimates?

No. CytomX Therapeutics reported EPS of −$0.09 for Q2 2026 against a −$0.08 estimate — a 16.73% miss.

### How much revenue did CTMX report last quarter?

CytomX Therapeutics reported $1.4M in revenue for Q2 2026, against a consensus estimate of $12.4M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).